Single Dose Replicating Poxvirus Vector-Based RBD Vaccine Drives Robust Humoral and T Cell Immune Response against SARS-CoV-2 Infection

To combat SARS-CoV-2, researchers characterized a temperature-stable vaccine candidate that used a replication-competent, attenuated vaccinia virus as a vector to express a membrane-tethered spike receptor binding domain (RBD) antigen.